Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

US-China GPCR Research Consortium Adds Two Pharma Members

publication date: Feb 10, 2015
The GPCR Consortium, a nonprofit US-China research collaboration, has added two new pharma members: Novo Nordisk and Merck. The academic members of the Consortium -- the Bridge Institute at the University of Southern California, the Shanghai Institute of Materia Medica, and the iHuman Institute at ShanghaiTech University -- remain the same. The Consortium's goal is to fully characterize the structure and function of 200 GPCRs, placing their findings in the public domain, with a goal of improving drug discovery. The companies underwrite the research performed at the academic institutes. More details.....

Stock Symbols: (NYSE: NVO) (NYSE: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China